DOI: https://doi.org/10.22141/2224-0713.3.97.2018.133679
Algorithm of using a set of laboratory biomarkers in patients with multiple sclerosis with diagnostic and prognostic aim
Abstract
Keywords
Full Text:
PDF (Українська)References
Негрич Т.І., Сорокін Б.В., Євтушенко С.К. Від вірогідної діагностики до ефективної терапії розсіяного склерозу // Міжнародний неврологічний журнал. — 2012. — № 3. — С. 152-158.
Kuhle J., Disanto G., Dobson R. et al. Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study // Multiple Sclerosis Journal. — 2015. — № 21(8). — Р. 1013-1024. doi: 10.1177/1352458514568827.
Thompson A.J., Banwell B.L., Barkhof F. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria // The Lancet Neurology. — 2017. — № 17(2). — Р. 162-173. doi: 10.1016/S1474-4422(17)30470-2.
Aliaga E.S., Barkhof F. MRI mimics of multiple sclerosis // Handbook of clinical neurology. — Elsevier, 2014. — Vol. 122. — Р. 291-316. doi: 10.1016/B978-0-444-52001-2.00012-1.
Dobson R., Ramagopala S., Davis A., Giovannoni G. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude // J. Neurol. Neurosurg. Psychiatry. — 2013. — jnnp-2012. doi: 10.1136/jnnp-2012-304695.
D’Ambrosio A., Pontecorvo S., Colasanti T., Zamboni S., Francia A., Margutti P. Peripheral blood biomarkers in multiple sclerosis // Autoimmunity reviews. — 2015. — Vol. 14(12). — Р. 1097-1110. doi: 10.1016/j.autrev.2015.07.014.
Marcus J.F., Waubant E.L. Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis // The Neurohospitalist. — 2013. — Vol. 3(2). — Р. 65-80. doi: 10.1177/1941874412457183.
Lublin F.D., Reingold S.C., Cohen J.A., Cutter G.R., Sørensen P.S., Thompson A.J., Bebo B. Defining the clinical course of multiple sclerosis. The 2013 revisions // Neurology. — 2014. — Vol. 83(3). — Р. 278-286. doi:10.1212/WNL.0000000000000560.
Wang H., Wang K., Wang C., Zhong X., Qiu W., Hu X. Increased plasma levels of pentraxin 3 in patients with multiple sclerosis and neuromyelitis optica // Multiple Sclerosis Journal. — 2013. — Vol. 19(7). — Р. 926-931. doi: 10.1177/1352458512457845.
Hein K., Köhler A., Diem R. et al. Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis // Neuroscience letters. — 2008. — Vol. 436(1). — Р. 72-76. doi: 10.1016/S1474-4422(04)00964-0.
Filippi M., Rocca M.A., Ciccarelli O. et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines // The Lancet Neurology. — 2016. — Vol. 15(3). — Р. 292-303. doi: 10.1016/S1474-4422(15)00393-2.
Teunissen C.E., Dijkstra C., Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis // The Lancet Neurology. — 2005. — Vol. 4(1). — Р. 32-41. doi: 10.1016/S1474-4422(04)00964-0.
Khalil M., Enzinger C., Langkammer C. et al. CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome // Multiple Sclerosis (Houndmills, Basingstoke, England). — 2013. — Vol. 19(4). — Р. 436-442. doi: 10.1177/1352458512458010.
Hosmer Jr D.W. Applied logistic regression / Hosmer Jr D.W., Lemeshow S., Sturdivant R.X. — John Wiley & Sons, 2013. — Vol. 398.
Aydin S. A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA // Peptides. — 2015. — Vol. 72. — Р. 4-15. doi: 10.1016/j.peptides.2015.04.012.
Link H., Huang Y.M. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness // Journal of neuroimmunology. — 2006. — Vol. 180(1). — Р. 17-28. doi: 10.1016/j.jneuroim.2006.07.006.
Srivastava R., Aslam M., Kalluri S.R. et al. Potassium channel KIR4. 1 as an immune target in multiple sclerosis // New England Journal of Medicine. — 2012. — Vol. 367(2). Р. 115-123. doi: 10.1056/NEJMoa1110740.
Husted C. Structural insight into the role of myelin basic protein in multiple sclerosis // Proceedings of the National Academy of Sciences of the United States of America. — 2006. — Vol. 103(12). — Р. 4339-4340. doi: 10.1073/pnas.0601002103.
Mayer M.C., Meinl E. Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more // Therapeutic advances in neurological disorders. — 2012. — Vol. 5(3). — Р. 147-159. doi: 10.1177/1756285611433772.
Schwarz M., Spector L., Gortler M. et al. Serum anti-Glc (α1, 4) Glc (α) antibodies as a biomarker for relapsing-remitting multiple sclerosis // Journal of the neurological sciences. — 2006. — Vol. 244(1). — Р. 59-68. doi: 10.1016/j.jns.2005.12.006.
Sundström P., Nyström M., Ruuth K., Lundgren E. Antibodies to specific EBNA-1 domains and HLA DRB11501 interact as risk factors for multiple sclerosis // Journal of neuroimmunology. — 2009. — Vol. 215(1). — Р. 102-107. doi: 10.1016/j.jneuroim.2009.08.004.
Myronovkij S., Negrych N., Nehrych T., Redowicz M.J., Souchelnytskyi S., Stoika R., Kit Y. Identification of a 48 kDa form of unconventional myosin 1c in blood serum of patients with autoimmune diseases // Biochemistry and biophysics reports. — 2016. — Vol. 5. — Р. 175-179. doi: 10.1016/j.bbrep.2015.12.001.
Petzold A. Intrathecal oligoclonal IgG synthesis in multiple sclerosis // J. Neuroimmunol. — 2013. — Vol. 262. — Р. 1-10. doi: 10.1016/j.jneuroim.2013.06.014.
Villar L.M., Masjuan J., Gonzalez-Porque P. et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS // Neurology. — 2002. — Vol. 59(4). — Р. 555-559. doi: 10.1212/WNL.59.4.555.
Brettschneider J., Tumani H., Kiechle U. et al. IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome // PloS Оne. — 2009. — Vol. 4(11). — Р. e7638. doi: 10.1371/journal.pone.0007638.
Senel M., Tumani H., Lauda F. et al. Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis // PLoS One. — 2014. — Vol. 9(4). — e88680. doi: 10.1371/journal.pone.0088680.
Marnetto F., Valentino P., Caldano M., Bertolotto A. Detection of potassium channel KIR4. 1 antibodies in Multiple Sclerosis patients // Journal of immunological methods. — 2017. — Vol. 445. — Р. 53-58. doi: 10.1016/j.jim.2017.03.008.
Reindl M., Di Pauli F., Rostásy K. Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases // Nat. Rev. Neurol. — 2013. — Vol. 9. — Р. 455-461. doi: 10.1038/nrneurol.2013.118.
Keller A., Leidinger P., Steinmeyer F. et al. Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing // Multiple Sclerosis Journal. — 2014. — Vol. 20(3). — Р. 295-303. doi: 10.1177/1352458513496343.
Teunissen C.E., Dijkstra C.D., Polman C.H., Hooger-
vorst E.L.J., Von Bergmann K., Lütjohann D. Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients // Neuroscience letters. — 2003. — Vol. 347(3). — Р. 159-162. doi: 10.1016/S0304-3940(03)00667-0.
Brettschneider J., Czerwoniak A., Senel M. et al. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS) // PloS Оne. — 2010. — Vol. 5(8). — e11986. doi: 10.1371/journal.pone.0011986.
Canto E., Tintore M., Villar L.M. et al. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes // Brain. — 2015. — Vol. 138(4). — Р. 918-931. doi: 10.1093/brain/
awv017.
Norgren N., Sundström P., Svenningsson A., Rosengren L., Stigbrand T., Gunnarsson M. Neurofilament and glial fibrillary acidic protein in multiple sclerosis // Neurology. — 2004. — Vol. 63(9). — Р. 1586-1590. doi: 10.1212/01.WNL.0000142988.49341.D1.
Trentini A., Comabella M., Tintoré M. et al. N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis // Journal of neurology. — 2014. — Vol. 261(12). — Р. 2338-2343. doi: 10.1007/s00415-014-7507-4.
Barateiro A., Afonso V., Santos G. et al. S100B as a potential biomarker and therapeutic target in multiple sclerosis // Molecular neurobiology. — 2016. — Vol. 53(6). — Р. 3976-3991. doi: 10.1007/s12035-015-9336-6.
Ummenthum K., Peferoen L.A., Finardi A. et al. Pentraxin-3 is upregulated in the central nervous system during MS and EAE, but does not modulate experimental neurological disease // European journal of immunology. — 2016. — Vol. 46(3). — Р. 701-711. doi: 10.1002/eji.201545950.
Comabella M., Pericot I., Goertsches R. et al. Plasma osteopontin levels in multiple sclerosis // Journal of neuroimmunology. — 2005. — Vol. 158(1). — Р. 231-239. doi: 10.1016/j.jneuroim.2004.09.004.
Trabattoni D., Saresella M., Pacei M. et al. Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease // The Journal of Immunology. — 2009. — Vol. 183(8). — Р. 4984-4993. doi: 10.4049/jimmunol.0901038.
Mirshafiey A., Asghari B., Ghalamfarsa G., Jadidi-Niaragh F., Azizi G. The Significance of Matrix Metalloproteinases in the Immunopathogenesis and Treatment of Multiple Sclerosis // Sultan Qaboos University Medical Journal. — 2014. — Vol. 14(1). — Р. 13-25. doi: 10.12816/0003332.
Moreno M., Sáenz-Cuesta M., Castilló J. et al. Circulating levels of soluble apoptosis-related molecules in patients with multiple sclerosis // Journal of neuroimmunology. — 2013. — Vol. 263(1). — Р. 152-154. doi: 10.1016/j.jneuroim.2013.07.013.
Sharief M.K., Noori M.A., Douglas M.R., Semra Y.K. Upregulated survivin expression in activated T lymphocytes correlates with disease activity in multiple sclerosis // European journal of neurology. — 2002. — Vol. 9(5). — Р. 503-510. doi: 10.1046/j.1468-1331.2002.00454.x.
Verderio C., Muzio L., Turola E. et al. Myeloid microvesicles are a marker and therapeutic target for neuroinflammation // Annals of neurology. — 2012. — Vol. 72(4). — Р. 610-624. doi: 10.1002/ana.23627.
Fenoglio C., Cantoni C., De Riz M. et al. Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis // Neuroscience letters. — 2011. — Vol. 504(1). — Р. 9-12. doi: 10.1016/j.neulet.2011.08.021.
Myronovkij S., Negrych N., Nehrych T., Tkachenko V., Souchelnytskyi S., Stoika R., Kit Y. Identification of SER-PRO-CYS Peptide in Blood Serum of Multiple Sclerosis Patients // Protein and peptide letters. — 2016. — Vol. 23(9). — Р. 808-811. doi: 10.2174/0929866523666160622215628.
Negrych N., Myronovskija S., Nehrych T. et al. Identification of the unique properties of IgGs and their heavy chains in blood serum of multiple sclerosis patients // Journal of Autoimmune Disorders. — 2016. — Vol. 2. — Р. 2. doi: 10.21767/2471-8513.100015.
Salzer J., Svenningsson A., Sundström P. Neurofilament light as a prognostic marker in multiple sclerosis // Multiple Sclerosis Journal. — 2010. — Vol. 16(3). — Р. 287-292. doi: 10.1177/1352458509359725.
Silber E., Semra Y.K., Gregson N.A., Sharief M.K. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit // Neurology. — 2002. — Vol. 58(9). — Р. 1372-1381. doi: 10.1212/WNL.58.9.1372.
Fenoglio C., Ridolfi E., Cantoni C. et al. Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis // Multiple Sclerosis Journal. — 2013. — Vol. 19(14). — Р. 1938-1942. doi: 10.1177/1352458513485654.
Koch M., Heersema D., Mostert J., Teelken A., Keyser J.D. Cerebrospinal fluid oligoclonal bands and progression of disability in multiple sclerosis // European journal of neurology. — Vol. 14(7). — Р. 797-800. doi: 10.1111/j.1468-1331.2007.01859.x.
Lourenco P., Shirani A., Saeedi J. et al. Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression // Multiple Sclerosis Journal. — 2013. — Vol. 19(5). — Р. 577-584. doi: 10.1177/1352458512459684.
Martínez M.A.M., Olsson B., Bau L. et al. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis // Multiple Sclerosis Journal. — 2015. — Vol. 21(5). — Р. 550-561. doi: 10.1177/1352458514549397.
Petzold A., Eikelenboom M.J., Gveric D. et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations // Brain. — 2002. — Vol. 125(7). — Р. 1462-1473. doi: 10.1093/brain/awf165.
Quintana F.J., Farez M.F., Viglietta V. et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis // Proceedings of the National Academy of Sciences. — 2008. — Vol. 105(48). — Р. 18889-18894. doi: 10.1073/pnas.0806310105.
Fissolo N., Cantó E., Vidal-Jordana A., Castilló J., Montalban X., Comabella M. Levels of soluble TNF-RII are increased in serum of patients with primary progressive multiple sclerosis // Journal of neuroimmunology. — 2014. — Vol. 271(1). — Р. 56-59. doi: 10.1016/j.jneuroim.2014.04.001.
Polman C.H., Bertolotto A., Deisenhammer F. et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis // The Lancet Neurology. — 2010. — Vol. 9(7). — Р. 740-750. doi: 10.1016/S1474-4422(10)70103-4.
Buck D., Cepok S., Hoffmann S. et al. Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis // Archives of neurology. — 2011. — Vol. 68(4). — Р. 480-487. doi: 10.1001/archneurol.2011.65.
Zula J.A., Green H.C., Ransohoff R.M., Rudick R.A., Stark G.R., van Boxel-Dezaire A.H. The role of cell type-specific responses in IFN-β therapy of multiple sclerosis // Proceedings of the National Academy of Sciences. — 2011. — Vol. 108(49). — Р. 19689-19694. doi: 10.1073/pnas.1117347108.
Comabella M., Río J., Espejo C. et al. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis // Clinical Immunology. — 2009. — Vol. 130(2). — Р. 145-150. doi: 10.1016/j.clim.2008.09.010.
Axtell R.C., De Jong B.A., Boniface K. et al. T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis // Nature medicine. — 2010. — Vol. 16(4). — Р. 406. doi: 10.1038/nm.2110.
Waschbisch A., Atiya M., Linker R.A., Potapov S., Schwab S., Derfuss T. Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis // Plo
Sone. — 2011. — Vol. 6(9). — Р. e24604. doi: 10.1371/journal.pone.0024604.
Rudick R.A., Ransohoff R.M., Lee J.C., Peppler R., Yu M., Mathisen P.M., Tuohy V.K. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis // Neurology. — 1998. — Vol. 50(5). — Р. 1294-1300. doi: 10.1212/
WNL.50.5.1294.
Calabresi P.A., Giovannoni G., Confavreux C. et al. The incidence and significance of anti-natalizumab antibodies Results from AFFIRM and SENTINEL // Neurology. — 2007. — Vol. 69(14). — Р. 1391-1403. doi: 10.1212/01.wnl.0000277457.17420.b5.
Lundkvist M., Engdahl E., Holmén C. et al. Characterization of anti-natalizumab antibodies in multiple sclerosis patients // Multiple Sclerosis Journal. — 2013. — Vol. 19(6). — Р. 757-764. doi: 10.1177/1352458512462920.
Plavina T., Subramanyam M., Bloomgren G. et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy // Annals of neurology. — 2014. — Vol. 76(6). — Р. 802-812. doi: 10.1002/ana.24286.
Schwab N., Schneider-Hohendorf T., Posevitz V. et al. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients // Neurology. — 2013. — Vol. 81(10). — Р. 865-871. doi: 10.1212/WNL.0b013e3182a351fb.
Copyright (c) 2018 INTERNATIONAL NEUROLOGICAL JOURNAL

This work is licensed under a Creative Commons Attribution 4.0 International License.
© Publishing House Zaslavsky, 1997-2020
